Liffert V.
- Country
- The Netherlands
- Department
- Department of Internal Medicine
Research Overview
- Efficacy and Safety of Oral BI 764198 in Adults and Adolescents with Primary or TRPC6-Variant Genetic Focal Segmental Glomerulosclerosis: A Randomized, Placebo-Controlled Trial
- Phase II Basket Trial of BI 764198 in Adults and Adolescents With Proteinuric Kidney Diseases
- Evaluation of R3R01 for Safety, Tolerability, and Efficacy in Alport Syndrome and Primary Steroid-Resistant Focal Segmental Glomerulosclerosis
Data & Insights
Has run more than one trial at 129 of 464 partner sites.
Specializations
Hypertension Management
The investigator specializes in treating uncontrolled and resistant hypertension, with particular focus on innovative therapeutic approaches. Their research explores antihypertensive interventions and blood pressure management strategies for patients who don't respond adequately to conventional treatments.
- Treatment-resistant hypertension
- Long-term blood pressure control
- Antihypertensive therapy optimization
Nephrology Expertise
The investigator focuses on chronic kidney disease and its relationship with hypertension. Their work extends to kidney transplantation procedures, particularly involving donation after circulatory death and prevention of ischemia reperfusion injury.
- Delayed graft function prevention
- End-stage kidney disease management
- Transplant outcomes optimization
Rare Kidney Disorders
The investigator has developed expertise in treating rare kidney conditions, including Alport Syndrome and Focal Segmental Glomerulosclerosis. Their research focuses on innovative therapeutic approaches for managing proteinuria in these challenging conditions.
- Proteinuria reduction strategies
- Steroid-resistant conditions
- Novel therapeutic applications
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.